Author(s)

Nesibe Karahan Yeşil¹, Hatice Şahin², Metin Işik^3*, Ziyaeddin Aktop⁴, İsmail Doğan⁵, Ali Erdem Baki⁶

¹Department of Rheumatology, Ankara Research and Education Hospital, Ankara, Turkey.
²Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.
³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Mevlana University, Konya, Turkey.
⁴Department of Cardiology, Bülent Ecevit University, Zonguldak, Turkey.
⁵Division of Rheumatology, Department of Internal Medicine, Çorum Hitit University, Çorum, Turkey.
⁶Department of Physical Medicine and Rheabilitation, Bülent Ecevit University, Zonguldak, Turkey.

Takayasu arteritis is a large vessel vasculitis of the young women with giant cells and granuloma formation. The diagnosis and management of the disease are really not so easy because of the insidious onset and the difficulties in assessment of disease activity. Nearly 60% of the patients are corticosteroid resistant or dependent and relapses are very frequent during taper of the dose [1]. The novel biologic agents as Anti-TNF, Rutiximab and Tocilizumab provide acceptable response rates with low toxicity. Herein, we reviewed the efficacy of Tocilizumab in Takayasu arteritis.

Takayasu Arteritis, Tocilizumab, Corticosteroid

Yeşil, N. , Şahin, H. , Işik, M. , Aktop, Z. , Doğan, İ. and Baki, A. (2015) The Efficacy of Tocilizumab for Takayasu Arteritis: Review of the Literatures. Open Journal of Rheumatology and Autoimmune Diseases, 5, 118-125. doi: 10.4236/ojra.2015.54019.